journal
MENU ▼
Read by QxMD icon Read
search

Neurology

journal
https://read.qxmd.com/read/30877188/comparative-effectiveness-of-teriflunomide-and-dimethyl-fumarate-a-nationwide-cohort-study
#1
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Jette Frederiksen, Monika Katarzyna Góra, Zsolt Illes, Matthias Kant, Zsolt Mezei, Thor Petersen, Peter Vestergaard Rasmussen, Homayoun Roshanisefat, Houry Hassanpour-Kalam-Roudy, Tobias Sejbæk, Anna Tsakiri, Arkadiusz Weglewski, Per Soelberg Sorensen, Melinda Magyari
OBJECTIVE: To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting. METHODS: We identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods. RESULTS: We included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF...
March 15, 2019: Neurology
https://read.qxmd.com/read/30877187/effectiveness-of-oral-multiple-sclerosis-therapies-in-clinical-context
#2
EDITORIAL
Tomas Kalincik
No abstract text is available yet for this article.
March 15, 2019: Neurology
https://read.qxmd.com/read/30877186/photosensitive-epilepsy-robust-clinical-efficacy-of-a-selective-gaba-potentiator
#3
Rachel Gurrell, Donal Gorman, Mark Whitlock, Adam Ogden, David S Reynolds, Bree DiVentura, Bassel Abou-Khalil, Michael Gelfand, John Pollard, R Edward Hogan, Gregory Krauss, Michael Sperling, Blanca Vazquez, Robert T Wechsler, Daniel Friedman, Richard P Butt, Jacqueline French
OBJECTIVE: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABAA receptors with minimal activity at α1-containing receptors, which are believed to mediate many of the adverse events associated with benzodiazepines, in the epilepsy photosensitivity model as a proof-of-principle of efficacy. METHODS: Seven participants with a photoparoxysmal response to intermittent photic stimulation (IPS) at baseline were randomized in a double-blind, 4-period cross-over study examining single doses of 17...
March 15, 2019: Neurology
https://read.qxmd.com/read/30867275/blood-brain-barrier-impairment-and-hypoperfusion-are-linked-in-cerebral-small-vessel-disease
#4
Sau May Wong, Jacobus F A Jansen, C Eleana Zhang, Erik I Hoff, Julie Staals, Robert J van Oostenbrugge, Walter H Backes
OBJECTIVE: To investigate the link between blood-brain-barrier (BBB) permeability and cerebral blood flow (CBF) and the relation with white matter hyperintensities (WMH) in cerebral small vessel disease (cSVD). METHODS: Twenty-seven patients with cSVD received dynamic susceptibility contrast and dynamic contrast-enhanced MRI to determine CBF and BBB permeability (expressed as leakage rate and volume), respectively. Structural MRI were segmented into normal-appearing white matter (NAWM) and WMH, for which a perilesional zone was defined...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867274/dynamic-gray-matter-volume-changes-in-pediatric-multiple-sclerosis-a-3-5-year-mri-study
#5
Ermelinda De Meo, Alessandro Meani, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti, Massimo Filippi, Maria A Rocca
OBJECTIVES: To assess, using MRI, the spatial patterns of gray matter (GM) atrophy in pediatric patients with multiple sclerosis (MS), their dynamic changes over time, and their clinical relevance. METHODS: Sixty-eight pediatric patients with MS (30 with a clinical and MRI follow-up after 3.5 years) and 26 healthy controls (HC) underwent clinical and MRI evaluation. To overcome difficulties in obtaining longitudinal scans in pediatric HC, a group of 317 pediatric HC from an NIH-funded MRI Study of Normal Brain Development was used to estimate GM developmental trajectories...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867273/-klotho-heterozygosity-attenuates-apoe4-related-amyloid-burden-in-preclinical-ad
#6
Claire M Erickson, Stephanie A Schultz, Jennifer M Oh, Burcu F Darst, Yue Ma, Derek Norton, Tobey Betthauser, Catherine L Gallagher, Cynthia M Carlsson, Barbara B Bendlin, Sanjay Asthana, Bruce P Hermann, Mark A Sager, Kaj Blennow, Henrik Zetterberg, Corinne D Engelman, Bradley T Christian, Sterling C Johnson, Dena B Dubal, Ozioma C Okonkwo
OBJECTIVE: To examine whether the KLOTHO gene variant KL-VS attenuates APOE4- associated β-amyloid (Aβ) accumulation in a late-middle-aged cohort enriched with Alzheimer disease (AD) risk factors. METHODS: Three hundred nine late-middle-aged adults from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center were genotyped to determine KL-VS and APOE4 status and underwent CSF sampling (n = 238) and/or 11 C-Pittsburgh compound B (PiB)-PET imaging (n = 183)...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867272/a-survey-of-risk-tolerance-to-multiple-sclerosis-therapies
#7
Robert J Fox, Carol Cosenza, Lauren Cripps, Paul Ford, MaryBeth Mercer, Sneha Natarajan, Amber Salter, Tuula Tyry, Stacey S Cofield
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple sclerosis (MS) therapies. METHODS: People with MS from the North American Research Committee on Multiple Sclerosis Registry's online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risks levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver injury, and progressive multifocal leukoencephalopathy (PML)...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867271/relative-risk-for-alzheimer-disease-based-on-complete-family-history
#8
Lisa A Cannon-Albright, Norman L Foster, Karen Schliep, James M Farnham, Craig C Teerlink, Heydon Kaddas, Joann Tschanz, Chris Corcoran, John S K Kauwe
OBJECTIVE: The inherited component for Alzheimer disease (AD) risk has focused on close relatives; consideration of the full family history may improve accuracy and utility of risk estimates. METHODS: A population resource including a genealogy of Utah pioneers from the 1800s linked to Utah death certificates was used to estimate relative risk for AD based on specific family history constellations, including from first- to third-degree relatives. RESULTS: Any affected first-degree relatives (FDR) significantly increased risk of AD (≥1 FDRs: relative risk [RR] 1...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867270/increase-of-arginine-dimethylation-correlates-with-the-progression-and-prognosis-of-als
#9
Kensuke Ikenaka, Naoki Atsuta, Yasuhiro Maeda, Yuji Hotta, Ryoichi Nakamura, Kaori Kawai, Daichi Yokoi, Akihiro Hirakawa, Akira Taniguchi, Mitsuya Morita, Kouichi Mizoguchi, Hideki Mochizuki, Kazunori Kimura, Masahisa Katsuno, Gen Sobue
OBJECTIVE: To investigate whether arginine methylation is altered in patients with amyotrophic lateral sclerosis (ALS) and how it affects disease severity, progression, and prognosis. METHODS: We compared the immunoreactivity of protein arginine methyltransferase 1 (PRMT1) and its products, asymmetric dimethylated proteins (ASYM), in postmortem spinal cord. We also measured the concentrations of total l-arginine and methylated arginine residues, including asymmetric dimethyl l-arginine (ADMA), symmetric dimethyl arginine, and monomethyl arginine, in CSF samples from 52 patients with ALS using liquid chromatography-tandem mass spectrometry, and we examined their relationship with the progression and prognosis of ALS...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867269/a-prospective-study-of-serum-metabolites-and-risk-of-ischemic-stroke
#10
Daokun Sun, Steffen Tiedt, Bing Yu, Xueqiu Jian, Rebecca F Gottesman, Thomas H Mosley, Eric Boerwinkle, Martin Dichgans, Myriam Fornage
OBJECTIVE: To identify promising blood-based biomarkers and novel etiologic pathways of disease risk, we applied an untargeted serum metabolomics profiling in a community-based prospective study of ischemic stroke (IS). METHODS: In 3,904 men and women from the Atherosclerosis Risk In Communities study, Cox proportional hazard models were used to estimate the association of incident IS with the standardized level of 245 fasting serum metabolites individually, adjusting for age, sex, race, field center, batch, diabetes, hypertension, current smoking status, body mass index, and estimated glomerular filtration rate...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867268/longevity-gene-klotho-may-play-a-role-in-alzheimer-disease
#11
Argonde C van Harten
No abstract text is available yet for this article.
March 13, 2019: Neurology
https://read.qxmd.com/read/30867267/white-matter-lesions-in-cerebral-small-vessel-disease-underperfusion-or-leaky-vessels
#12
EDITORIAL
Atticus H Hainsworth
No abstract text is available yet for this article.
March 13, 2019: Neurology
https://read.qxmd.com/read/30867266/measurement-of-symptoms-in-idiopathic-hypersomnia-the-idiopathic-hypersomnia-severity-scale
#13
Yves Dauvilliers, Elisa Evangelista, Lucie Barateau, Regis Lopez, Sofiène Chenini, Caroline Delbos, Séverine Beziat, Isabelle Jaussent
OBJECTIVE: To validate the Idiopathic Hypersomnia Severity Scale (IIHSS), a self-report measure of hypersomnolence symptoms, consequences, and responsiveness to treatment. METHODS: The 14-item IHSS (developed and validated by sleep experts with patients' feedback) was filled in by 218 participants (2.3% missing data). Among the 210 participants who fully completed the IHSS, there were 57 untreated and 43 treated patients with idiopathic hypersomnia (IH) aged 16 years or older, 37 untreated patients with narcolepsy type 1 (NT1), and 73 controls without sleepiness...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867265/evolution-of-regional-brain-atrophy-in-children-with-multiple-sclerosis-gray-matters
#14
EDITORIAL
E Ann Yeh, Arman Eshaghi
No abstract text is available yet for this article.
March 13, 2019: Neurology
https://read.qxmd.com/read/30867264/clinical-manifestations-of-homozygote-allele-carriers-in-huntington-disease
#15
Esther Cubo, Saul-Indra Martinez-Horta, Frederic Sampedro Santalo, Asunción Martínez Descalls, Sara Calvo, Cecilia Gil-Polo, Ignacio Muñoz, Katia Llano, Natividad Mariscal, Dolores Diaz, Aranzazu Gutierrez, Laura Aguado, María A Ramos-Arroyo
OBJECTIVE: Because patients homozygous for Huntington disease (HD) receive the gain-of-function mutation in a double dose, one would expect a more toxic effect in homozygotes than in heterozygotes. Our aim was to investigate the phenotypic differences between homozygotes with both alleles ≥36 CAG repeats and heterozygotes with 1 allele ≥36 CAG repeats. METHODS: This was an international, longitudinal, case-control study (European Huntington's Disease Network Registry database)...
March 13, 2019: Neurology
https://read.qxmd.com/read/30867263/patient-perceived-risks-of-ms-dmts-problems-of-communication-and-risk-management
#16
EDITORIAL
Gavin V McDonnell, James J Marriott
No abstract text is available yet for this article.
March 13, 2019: Neurology
https://read.qxmd.com/read/30850446/lower-serum-retinoic-acid-level-for-prediction-of-higher-risk-of-mortality-in-ischemic-stroke
#17
Wen-Jun Tu, Han-Cheng Qiu, Yiqun Zhang, Jian-Lei Cao, Hong Wang, Ji-Zong Zhao, Qiang Liu, Xianwei Zeng
OBJECTIVE: To explore the association between serum retinoic acid (RA) level in patients with acute ischemic stroke (AIS) and mortality risk in the 6 months after admission. METHODS: From January 2015 through December 2016, patients admitted to 3 stroke centers in China for first-ever AIS were screened. The primary endpoint was all-cause mortality or cardiovascular disease (CVD) mortality in the 6 months after admission. The significance of serum RA level, NIH Stroke Scale score, and established risk factors in predicting mortality were determined...
March 8, 2019: Neurology
https://read.qxmd.com/read/30850445/how-much-do-periventricular-lesions-assist-in-distinguishing-migraine-with-aura-from-cis
#18
Caterina Lapucci, Laura Saitta, Giulia Bommarito, Maria Pia Sormani, Matteo Pardini, Laura Bonzano, Giovanni Luigi Mancardi, Claudio Gasperini, Antonio Giorgio, Matilde Inglese, Nicola De Stefano, Luca Roccatagliata
OBJECTIVE: To evaluate in clinically isolated syndrome (CIS) and migraine with aura (MA) how the number of periventricular lesions (PVLs) detected at MRI influences diagnostic performance when the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) or the 2017 revised criteria are applied. METHODS: In this retrospective study, white matter hyperintensities (WMH) of 84 patients with MA and 79 patients with CIS were assessed using manual segmentation technique...
March 8, 2019: Neurology
https://read.qxmd.com/read/30850444/clinical-relevance-of-acute-cerebral-microinfarcts-in-vascular-cognitive-impairment
#19
Doeschka A Ferro, Hilde van den Brink, Lieza G Exalto, Jooske M F Boomsma, Frederik Barkhof, Niels D Prins, Wiesje M van der Flier, Geert Jan Biessels
OBJECTIVE: To determine the occurrence of acute cerebral microinfarcts (ACMIs) in memory clinic patients and relate their presence to vascular risk and cognitive profile, CSF and neuroimaging markers, and clinical outcome. METHODS: The TRACE-VCI study is a memory clinic cohort of patients with vascular brain injury on MRI (i.e., possible vascular cognitive impairment [VCI]). We included 783 patients (mean age 67.6 ± 8.5, 46% female) with available 3T diffusion-weighted imaging (DWI)...
March 8, 2019: Neurology
https://read.qxmd.com/read/30850443/neuromuscular-adverse-events-associated-with-anti-pd-1-monoclonal-antibodies-systematic-review
#20
REVIEW
Annette Johansen, Søren Just Christensen, David Scheie, Joan L S Højgaard, Daniel Kondziella
Neuromuscular adverse events following cancer treatment with anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We performed a systematic review to characterize the clinical presentation, diagnostic workup, and management of neuromuscular disorders (NMDs) in patients treated with nivolumab or pembrolizumab monotherapy or concurrent with other immunologic agents, such as ipilimumab. Sixty-one publications on 85 patients (mean age 66.9 years [range 34-86]; male/female 2...
March 8, 2019: Neurology
journal
journal
20202
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"